Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs

Signature Cytokines and Immune-Mediated Inflammatory Diseases The ability to block specific cytokine pathways has revealed pathophysiological differences among autoimmune diseases (e.g., the efficacy of TNF inhibitors in arthritides and inflammatory bowel disorders and their inefficacy in giant-cell arteritis and multiple sclerosis), providing a framework for reclassification.

Automated summary

The ability to block specific cytokine pathways has revealed pathophysiological differences among autoimmune diseases, providing a framework for reclassification based on the efficacy of treatments like TNF inhibitors in certain diseases but not others.